Does COVID-19 Increase the Risk of Subsequent Kidney Diseases More Than Influenza? A Retrospective Cohort Study Using Real-World Data In the United States

Yue Zhang,Nasrollah Ghahramani,Vernon M. Chinchilli,Djibril M. Ba
DOI: https://doi.org/10.1101/2024.06.27.24309556
2024-06-28
Abstract:Background: Although case reports and observational studies suggest Coronavirus disease 2019 (COVID-19) increases the risk of kidney diseases, definitive real-world evidence, especially in comparison with influenza, is lacking. Our study aims to assess the association between COVID-19 infections and subsequent kidney diseases, using influenza as a positive control and incorporating a negative control to establish clearer associations. Methods: A large retrospective cohort study with strata matching was conducted using the MarketScan database with records from Jan. 2020 to Dec. 2021. We used the international classification of 10th revision (ICD-10) codes to identify individuals and build three cohorts, (1) COVID-19 group, with index dates as the diagnosis dates of COVID-19; (2) Influenza but no COVID-19 (positive control) group, with index dates as the diagnosis dates of Influenza; and (3) no COVID-19 / Influenza (negative control) group, with randomly assigned index dates between Jan. 2020 to Dec. 2021. The main outcomes were acute kidney injury (AKI), chronic kidney disease (CKD), and end-stage renal disease (ESRD). To evaluate the association between COVID-19 and the new onset of kidney diseases relative to both control groups, we employed multivariable stratified Cox proportional hazards regression analysis. Results: The study included 939,241 individuals with COVID-19, 1,878,482 individuals in the negative control group, and 199,071 individuals with influenza. After adjusting for demographics, comorbidities, and medication histories, COVID-19 was significantly associated with increased risks of AKI (adjusted hazards ratio, aHR: 2.74, 2.61-2.87), CKD (aHR: 1.38, 1.32-1.45), and ESRD (aHR, 3.22; 95% CI, 2.67-3.88), while influenza was associated with a modestly increased risk of AKI (aHR: 1.24, 1.11-1.38) and had no impact on CKD (aHR: 1.03, 0.92-1.14), and ESRD (aHR, 0.84; 95% CI, 0.55-1.29). Time-specific analyses indicated that while the HR for AKI declined from 0-180 days to 0-540 days, the HR for CKD and ESRD remained stable, with COVID-19's risk surpassing influenza's risk throughout follow-up. Exploratory analysis also found significant impacts of COVID-19 on glomerular diseases (aHR 1.28, 95% CI 1.09-1.50). Conclusion: In this large real-world study, COVID-19 infections were associated with a 2.3-fold risk of developing AKI, a 1.4-fold risk of CKD, and a 4.7-fold risk of ESRD compared to influenza. Greater attention needs to be paid to kidney diseases in individuals after contracting COVID-19 to prevent future adverse health outcomes.
Epidemiology
What problem does this paper attempt to address?
The purpose of this paper is to explore and compare the impact of COVID-19 and influenza on the subsequent risk of kidney diseases. Specifically, the study aims to assess the risks of acute kidney injury (AKI), chronic kidney disease (CKD), and end-stage renal disease (ESRD) following COVID-19 infection and to compare these risks with the corresponding risks after influenza infection. The study employed a retrospective cohort study design, utilizing real-world data from the United States (MarketScan database), spanning from January 2020 to December 2021. Three cohorts were defined in the study: 1. **COVID-19 group**: Patients diagnosed with COVID-19. 2. **Influenza group (positive control group)**: Individuals who only had influenza without COVID-19 infection. 3. **No COVID-19/Influenza group (negative control group)**: Individuals with no history of either COVID-19 or influenza. Potential confounding factors such as age, gender, and region were controlled using matched analysis methods. The primary outcome measures included the incidence of new cases of AKI, CKD, and ESRD. The study employed multivariable stratified Cox proportional hazards regression analysis to assess the association between COVID-19 and the onset of new kidney diseases, comparing it with the two control groups. The results of the study indicated that, compared to influenza, COVID-19 infection significantly increased the risks of AKI, CKD, and ESRD. The risk of AKI in COVID-19 patients increased by approximately 2.7 times, the risk of CKD by about 1.4 times, and the risk of ESRD by about 4.7 times. Additionally, the study found that the risk of glomerular diseases also increased after COVID-19 infection. In conclusion, this study provides large-scale real-world evidence that the long-term risk of developing kidney diseases after COVID-19 infection is significantly higher than that following influenza. This suggests that we need to pay more attention to the potential kidney health issues in COVID-19 survivors to prevent future adverse health outcomes.